{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,2]],"date-time":"2026-10-02T04:54:20Z","timestamp":1790916860956,"version":"4.1.0"},"reference-count":80,"publisher":"Bentham Science Publishers Ltd.","issue":"3","content-domain":{"domain":["eurekaselect.com"],"crossmark-restriction":true},"short-container-title":["CDM"],"published-print":{"date-parts":[[2026,5]]},"abstract":"<jats:sec>\n                    <jats:title\/>\n                    <jats:p>Bioactivation and clearance of anticancer agents are crucial factors in the efficacy\nand toxicity of anticancer drugs. Exosomes are membrane-bound vesicles secreted by tumor\ncells and the tumor microenvironment. These vesicles contain drug-metabolizing enzymes,\ntransporters, and RNA. Exosomes can be non-invasively collected from the blood. This article\nhas been prepared by combining the evidence of the role of exosomal cytochrome P450\nisoforms, such as cytochrome P450 family 2 subfamily C member 19, cytochrome P450 family\n2 subfamily D member 6, and cytochrome P450 family 3 subfamily A member 5, in the oxidation\nof anticancer drugs in the first phase of drug metabolism. Exosomal UDP-glucuronosyltransferase\n1A1 has been found to help in the conjugation of anticancer drugs in the second\nphase of drug metabolism. Exosomal ATP-binding cassette transporters, P-glycoprotein, multidrug\nresistance-associated protein 1, and breast cancer resistance protein have been found to\nact as intercellular conveyors of drug efflux capacity. These transporters can modulate the efficacy\nof chemotherapy. Exosomal microRNAs, such as microRNA-21, microRNA-155, and\nmicroRNA-1246, have been found to modulate apoptosis, DNA repair, metabolic adaptation,\nand chemotherapy resistance through the PI3K\/AKT pathway, EZH2\/STAT3 pathway, and\nPDCD4 pathway. Long non-coding RNAs, such as UCA1 and HOXA antisense RNA, can\nreprogram the chromatin structure. These long non-coding RNAs can suppress tumor suppressor\ngenes, thus leading to chemotherapy resistance. Bioinformatics pipelines have been designed\nto bridge the gap between exosomal RNA and protein levels in the profile of dynamic\nmetabolic states. The challenges in the field of exosomal therapy drug monitoring have been\ndiscussed in the article. The article has recommended the use of artificial intelligence in the\nintegration of omics with microfluidic technology for the improvement of exosomal therapy\ndrug monitoring.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.2174\/0113892002399475260223055432","type":"journal-article","created":{"date-parts":[[2026,3,29]],"date-time":"2026-03-29T18:32:09Z","timestamp":1774809129000},"page":"174-187","update-policy":"https:\/\/doi.org\/10.2174\/bsp_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["The Role of Exosomal Biomarkers in the Monitoring of Bioactivation and Metabolite Clearance of Chemotherapeutics in Cancer Patients"],"prefix":"10.2174","volume":"27","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-7179-1143","authenticated-orcid":true,"given":"Satheesh","family":"S.","sequence":"first","affiliation":[{"name":"Department of Pharmacy Practice, JKKN College of Pharmacy, Kumarapalayam, Namakkal, India"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0008-0538-0280","authenticated-orcid":true,"given":"Sekar","family":"V.","sequence":"additional","affiliation":[{"name":"Department of Pharmaceutical Analysis, JKKN College of Pharmacy, Kumarapalayam, Namakkal, India"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0008-0603-0338","authenticated-orcid":true,"given":"Kaarnika","family":"V.S.","sequence":"additional","affiliation":[{"name":"PSG Institute of Medical Sciences and Research, Coimbatore, India"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0009-7985-5274","authenticated-orcid":true,"given":"Maageswaree","family":"B.S.","sequence":"additional","affiliation":[{"name":"Department of Pharmaceutical Analysis, JKKN College of Pharmacy, Kumarapalayam, Namakkal, India"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0004-7981-5161","authenticated-orcid":true,"given":"Bhoopendra","family":"G.K.","sequence":"additional","affiliation":[{"name":"Department of Pharmaceutical Analysis, JKKN College of Pharmacy, Kumarapalayam, Namakkal, India"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0006-5271-7988","authenticated-orcid":true,"given":"Ibrahim","family":"B.","sequence":"additional","affiliation":[{"name":"Department of Pharmaceutical Analysis, JKKN College of Pharmacy, Kumarapalayam, Namakkal, India"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0001-3007-2027","authenticated-orcid":true,"given":"Nithish","family":"S.","sequence":"additional","affiliation":[{"name":"Department of Pharmaceutical Analysis, JKKN College of Pharmacy, Kumarapalayam, Namakkal, India"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0008-3562-3060","authenticated-orcid":true,"given":"Gowtham","family":"V.","sequence":"additional","affiliation":[{"name":"Department of Pharmaceutical Analysis, JKKN College of Pharmacy, Kumarapalayam, Namakkal, India"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"965","reference":[{"key":"ref=1","doi-asserted-by":"publisher","first-page":"864","DOI":"10.3390\/biom15060864","volume":"15","author":"Lin K.","year":"2025","unstructured":"Lin K.; Wang R.; Li T.; Drug transporters and metabolizing enzymes in antimicrobial drug pharmacokinetics: Mechanisms, drug\u2013drug interactions, and clinical implications. Biomolecules  2025,15(6),864","journal-title":"Biomolecules"},{"key":"ref=2","doi-asserted-by":"publisher","first-page":"113","DOI":"10.1007\/978-1-4613-4349-3_11","volume":"2","author":"Sadee W.","year":"1976","unstructured":"Sadee W.; Pharmacokinetics of anticancer drugs. Chemotherapy  1976,2,113-117","journal-title":"Chemotherapy"},{"key":"ref=3","doi-asserted-by":"publisher","first-page":"517","DOI":"10.1016\/j.mpaic.2020.07.001","volume":"21","author":"Vaja R.","year":"2020","unstructured":"Vaja R.; Rana M.; Drugs and the liver. Anaesth Intensive Care Med  2020,21(10),517-523","journal-title":"Anaesth Intensive Care Med"},{"key":"ref=4","doi-asserted-by":"publisher","first-page":"e70096","DOI":"10.1002\/cam4.70096","volume":"13","author":"Wong M.H.","year":"2024","unstructured":"Wong M.H.; Jones V.C.; Yu W.; Bosserman L.D.; Lavasani S.M.; Patel N.; Sedrak M.S.; Stewart D.B.; Waisman J.R.; Yuan Y.; Mortimer J.E.; UGT1A1*28 polymorphism and the risk of toxicity and disease progression in patients with breast cancer receiving sacituzumab govitecan. Cancer Med  2024,13(16),e70096","journal-title":"Cancer Med"},{"key":"ref=5","doi-asserted-by":"publisher","first-page":"1290","DOI":"10.1093\/jnci\/djm115","volume":"99","author":"Hoskins J.M.","year":"2007","unstructured":"Hoskins J.M.; Goldberg R.M.; Qu P.; Ibrahim J.G.; McLeod H.L.; UGT1A1*28 genotype and irinotecan-induced neutropenia: Dose matters. J Natl Cancer Inst  2007,99(17),1290-1295","journal-title":"J Natl Cancer Inst"},{"key":"ref=6","doi-asserted-by":"publisher","first-page":"988","DOI":"10.3390\/ijms26030988","volume":"26","author":"Kurian R.","year":"2025","unstructured":"Kurian R.; Wang H.; Prodrugs in oncology: Bioactivation and impact on therapeutic efficacy and toxicity. Int J Mol Sci  2025,26(3),988","journal-title":"Int J Mol Sci"},{"key":"ref=7","first-page":"4409","volume":"6","author":"Ikeda K.","year":"2000","unstructured":"Ikeda K.; Yoshisue K.; Matsushima E.; Nagayama S.; Kobayashi K.; Tyson C.A.; Chiba K.; Kawaguchi Y.; Bioactivation of tegafur to 5-fluorouracil is catalyzed by cytochrome P-450 2A6 in human liver microsomes in vitro. Clin Cancer Res  2000,6(11),4409-4415","journal-title":"Clin Cancer Res"},{"key":"ref=8","doi-asserted-by":"publisher","first-page":"13923","DOI":"10.3390\/ijms232213923","volume":"23","author":"De Luca O.","year":"2022","unstructured":"De Luca O.; Salerno G.; De Bernardini D.; Lionetto L.; Gentile G.; Borro M.; Predicting dihydropyrimidine dehydrogenase deficiency and related 5-Fluorouracil toxicity: Opportunities and challenges of DPYD exon sequencing and the role of phenotyping assays. Int J Mol Sci  2022,23(22),13923","journal-title":"Int J Mol Sci"},{"key":"ref=9","doi-asserted-by":"publisher","first-page":"228","DOI":"10.2478\/aiht-2024-75-3923","volume":"75","author":"Vucemilovic A.","year":"2024","unstructured":"Vucemilovic A.; Exosomes: Intriguing mediators of intercellular communication in the organism's response to noxious agents. Archiv Industr Hygien Toxicol  2024,75(4),228-239","journal-title":"Archiv Industr Hygien Toxicol"},{"key":"ref=10","doi-asserted-by":"publisher","first-page":"1052731","DOI":"10.3389\/fgene.2023.1052731","volume":"14","author":"Alotaibi F.","year":"2023","unstructured":"Alotaibi F.; Exosomal microRNAs in cancer: Potential biomarkers and immunotherapeutic targets for immune checkpoint molecules. Front Genet  2023,14,1052731","journal-title":"Front Genet"},{"key":"ref=11","doi-asserted-by":"publisher","first-page":"90","DOI":"10.1016\/j.tcb.2023.06.006","volume":"34","author":"Arya S.B.","year":"2024","unstructured":"Arya S.B.; Collie S.P.; Parent C.A.; The ins-and-outs of exosome biogenesis, secretion, and internalization. Trends Cell Biol  2024,34(2),90-108","journal-title":"Trends Cell Biol"},{"key":"ref=12","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1186\/s13578-019-0282-2","volume":"9","author":"Zhang Y.","year":"2019","unstructured":"Zhang Y.; Liu Y.; Liu H.; Tang W.H.; Exosomes: Biogenesis, biologic function and clinical potential. Cell Biosci  2019,9(1),19","journal-title":"Cell Biosci"},{"key":"ref=13","doi-asserted-by":"publisher","first-page":"193","DOI":"10.1007\/s00018-017-2595-9","volume":"75","author":"Hessvik N.P.","year":"2018","unstructured":"Hessvik N.P.; Llorente A.; Current knowledge on exosome biogenesis and release. Cell Mol Life Sci  2018,75(2),193-208","journal-title":"Cell Mol Life Sci"},{"key":"ref=14","doi-asserted-by":"publisher","first-page":"47","DOI":"10.1186\/s12964-021-00730-1","volume":"19","author":"Gurung S.","year":"2021","unstructured":"Gurung S.; Perocheau D.; Touramanidou L.; Baruteau J.; The exosome journey: From biogenesis to uptake and intracellular signalling. Cell Commun Signal  2021,19(1),47","journal-title":"Cell Commun Signal"},{"key":"ref=15","doi-asserted-by":"publisher","first-page":"1894","DOI":"10.1016\/j.gendis.2022.03.021","volume":"10","author":"Xu M.","year":"2023","unstructured":"Xu M.; Ji J.; Jin D.; Wu Y.; Wu T.; Lin R.; Zhu S.; Jiang F.; Ji Y.; Bao B.; Li M.; Xu W.; Xiao M.; The biogenesis and secretion of exosomes and multivesicular bodies (MVBs): Intercellular shuttles and implications in human diseases. Genes Dis  2023,10(5),1894-1907","journal-title":"Genes Dis"},{"key":"ref=16","doi-asserted-by":"publisher","first-page":"19","DOI":"10.1038\/ncb2000","volume":"12","author":"Ostrowski M.","year":"2010","unstructured":"Ostrowski M.; Carmo N.B.; Krumeich S.; Fanget I.; Raposo G.; Savina A.; Moita C.F.; Schauer K.; Hume A.N.; Freitas R.P.; Goud B.; Benaroch P.; Hacohen N.; Fukuda M.; Desnos C.; Seabra M.C.; Darchen F.; Amigorena S.; Moita L.F.; Thery C.; Rab27a and Rab27b control different steps of the exosome secretion pathway. Nat Cell Biol  1-132010,12(1),19-30","journal-title":"Nat Cell Biol"},{"key":"ref=17","doi-asserted-by":"publisher","first-page":"1413","DOI":"10.1016\/j.eng.2020.08.013","volume":"7","author":"Mu W.","year":"2021","unstructured":"Mu W.; Xu Y.; Gu P.; Wang W.; Li J.; Ge Y.; Wang H.; Exosomal CD44 cooperates with integrin \u03b16\u03b24 to support organotropic metastasis via regulating tumor cell motility and target host cell activation. Engineering  2021,7(10),1413-1423","journal-title":"Engineering"},{"key":"ref=18","doi-asserted-by":"publisher","first-page":"9","DOI":"10.1194\/jlr.R084343","volume":"60","author":"Skotland T.","year":"2019","unstructured":"Skotland T.; Hessvik N.P.; Sandvig K.; Llorente A.; Exosomal lipid composition and the role of ether lipids and phosphoinositides in exosome biology. J Lipid Res  2019,60(1),9-18","journal-title":"J Lipid Res"},{"key":"ref=19","doi-asserted-by":"publisher","first-page":"7","DOI":"10.1016\/j.ncrna.2022.01.001","volume":"7","author":"Narang P.","year":"2022","unstructured":"Narang P.; Shah M.; Beljanski V.; Exosomal RNAs in diagnosis and therapies. Noncoding RNA Res  2022,7(1),7-15","journal-title":"Noncoding RNA Res"},{"key":"ref=20","doi-asserted-by":"publisher","first-page":"13","DOI":"10.1186\/s12943-024-02215-4","volume":"24","author":"Li J.","year":"2025","unstructured":"Li J.; Wang J.; Chen Z.; Emerging role of exosomes in cancer therapy: Progress and challenges. Mol Cancer  2025,24(1),13","journal-title":"Mol Cancer"},{"key":"ref=21","doi-asserted-by":"publisher","first-page":"5369","DOI":"10.1038\/onc.2017.134","volume":"36","author":"Zeng A.-L.","year":"2017","unstructured":"Zeng A.-L.; Yan W.; Liu Y.-W.; Wang Z.; Hu Q.; Nie E.; Zhou X.; Li R.; Wang X.-F.; Jiang T.; You Y.-P.; Tumour exosomes from cells harbouring PTPRZ1\u2013MET fusion contribute to a malignant phenotype and temozolomide chemoresistance in glioblastoma. Oncogene  2017,36(38),5369-5381","journal-title":"Oncogene"},{"key":"ref=22","doi-asserted-by":"publisher","first-page":"43","DOI":"10.20517\/cdr.2024.97","volume":"7","author":"Pan W.","year":"2024","unstructured":"Pan W.; Miao Q.; Yin W.; Li X.; Ye W.; Zhang D.; Deng L.; Zhang J.; Chen M.; The role and clinical applications of exosomes in cancer drug resistance. Cancer Drug Resist  2024,7,43","journal-title":"Cancer Drug Resist"},{"key":"ref=23","doi-asserted-by":"publisher","first-page":"45","DOI":"10.1186\/s12943-025-02233-w","volume":"24","author":"Kuang L.","year":"2025","unstructured":"Kuang L.; Wu L.; Li Y.; Extracellular vesicles in tumor immunity: Mechanisms and novel insights. Mol Cancer  2025,24(1),45","journal-title":"Mol Cancer"},{"key":"ref=24","doi-asserted-by":"publisher","first-page":"4","DOI":"10.3390\/medsci12010004","volume":"12","author":"Ateeq M.","year":"2024","unstructured":"Ateeq M.; Broadwin M.; Sellke F.W.; Abid M.R.; Extracellular vesicles\u2019 role in angiogenesis and altering angiogenic signaling. Med Sci  2024,12(1),4","journal-title":"Med Sci"},{"key":"ref=25","doi-asserted-by":"publisher","first-page":"10","DOI":"10.1186\/s12943-018-0928-4","volume":"18","author":"Jiang X.","year":"2019","unstructured":"Jiang X.; Wang J.; Deng X.; Xiong F.; Ge J.; Xiang B.; Wu X.; Ma J.; Zhou M.; Li X.; Li Y.; Li G.; Xiong W.; Guo C.; Zeng Z.; Role of the tumor microenvironment in PD-L1\/PD-1-mediated tumor immune escape. Mol Cancer  2019,18(1),10","journal-title":"Mol Cancer"},{"key":"ref=26","doi-asserted-by":"publisher","first-page":"1942","DOI":"10.3390\/ijms25031942","volume":"25","author":"Gaal Z.","year":"2024","unstructured":"Gaal Z.; Role of microRNAs in immune regulation with translational and clinical applications. Int J Mol Sci  2024,25(3),1942","journal-title":"Int J Mol Sci"},{"key":"ref=27","doi-asserted-by":"publisher","first-page":"3","DOI":"10.1016\/j.semcdb.2017.01.004","volume":"67","author":"Lobb R.J.","year":"2017","unstructured":"Lobb R.J.; Lima L.G.; M\u00f6ller A.; Exosomes: Key mediators of metastasis and pre-metastatic niche formation. Semin Cell Dev Biol  2017,67,3-10","journal-title":"Semin Cell Dev Biol"},{"key":"ref=28","doi-asserted-by":"publisher","first-page":"e28231","DOI":"10.4161\/cib.28231","volume":"7","author":"Atay S.","year":"2014","unstructured":"Atay S.; Godwin A.K.; Tumor-derived exosomes. Commun Integr Biol  2014,7(1),e28231","journal-title":"Commun Integr Biol"},{"key":"ref=29","doi-asserted-by":"publisher","first-page":"69","DOI":"10.3390\/vaccines6040069","volume":"6","author":"Jella K.K.","year":"2018","unstructured":"Jella K.K.; Nasti T.H.; Li Z.; Malla S.R.; Buchwald Z.S.; Khan M.K.; Exosomes, their biogenesis and role in inter-cellular communication, tumor microenvironment and cancer immunotherapy. Vaccines  2018,6(4),69","journal-title":"Vaccines"},{"key":"ref=30","doi-asserted-by":"publisher","first-page":"767","DOI":"10.3390\/biomedicines10040767","volume":"10","author":"Vig S.","year":"2022","unstructured":"Vig S.; Fernandes M.H.; Bone cell exosomes and emerging strategies in bone engineering. Biomedicines  2022,10(4),767","journal-title":"Biomedicines"},{"key":"ref=31","doi-asserted-by":"publisher","first-page":"883","DOI":"10.1038\/nm.2753","volume":"18","author":"Peinado H.","year":"2012","unstructured":"Peinado H.; Ale\u010dkovi\u0107 M.; Lavotshkin S.; Matei I.; Costa-Silva B.; Moreno-Bueno G.; Hergueta-Redondo M.; Williams C.; Garc\u00eda-Santos G.; Ghajar C.M.; Nitadori-Hoshino A.; Hoffman C.; Badal K.; Garcia B.A.; Callahan M.K.; Yuan J.; Martins V.R.; Skog J.; Kaplan R.N.; Brady M.S.; Wolchok J.D.; Chapman P.B.; Kang Y.; Bromberg J.; Lyden D.; Melanoma exosomes educate bone marrow progenitor cells toward a pro-metastatic phenotype through MET. Nat Med  2012,18(6),883-891","journal-title":"Nat Med"},{"key":"ref=32","doi-asserted-by":"publisher","first-page":"39","DOI":"10.1186\/s12943-019-0995-1","volume":"18","author":"Guo Y.","year":"2019","unstructured":"Guo Y.; Ji X.; Liu J.; Fan D.; Zhou Q.; Chen C.; Wang W.; Wang G.; Wang H.; Yuan W.; Ji Z.; Sun Z.; Effects of exosomes on pre-metastatic niche formation in tumors. Mol Cancer  2019,18(1),39","journal-title":"Mol Cancer"},{"key":"ref=33","doi-asserted-by":"publisher","first-page":"10773","DOI":"10.1007\/s13277-014-2377-z","volume":"35","author":"Lv M.","year":"2014","unstructured":"Lv M.; Zhu X.; Chen W.; Zhong S.; Hu Q.; Ma T.; Zhang J.; Chen L.; Tang J.; Zhao J.; Exosomes mediate drug resistance transfer in MCF-7 breast cancer cells and a probable mechanism is delivery of P-glycoprotein. Tumour Biol  2014,35(11),10773-10779","journal-title":"Tumour Biol"},{"key":"ref=34","doi-asserted-by":"publisher","first-page":"100","DOI":"10.1016\/j.ebiom.2018.11.004","volume":"38","author":"Kanlikilicer P.","year":"2018","unstructured":"Kanlikilicer P.; Bayraktar R.; Denizli M.; Rashed M.H.; Ivan C.; Aslan B.; Mitra R.; Karagoz K.; Bayraktar E.; Zhang X.; Rodriguez-Aguayo C.; El-Arabey A.A.; Kahraman N.; Baydogan S.; Ozkayar O.; Gatza M.L.; Ozpolat B.; Calin G.A.; Sood A.K.; Lopez-Berestein G.; Exosomal miRNA confers chemo resistance via targeting Cav1\/p-gp\/M2-type macrophage axis in ovarian cancer. EBioMedicine  2018,38,100-112","journal-title":"EBioMedicine"},{"key":"ref=35","doi-asserted-by":"publisher","first-page":"66","DOI":"10.1016\/j.canlet.2021.05.031","volume":"517","author":"Chang W.H.","year":"2021","unstructured":"Chang W.H.; Nguyen T.T.T.; Hsu C.H.; Bryant K.L.; Kim H.J.; Ying H.; Erickson J.W.; Der C.J.; Cerione R.A.; Antonyak M.A.; KRAS-dependent cancer cells promote survival by producing exosomes enriched in Survivin. Cancer Lett  2021,517,66-77","journal-title":"Cancer Lett"},{"key":"ref=36","doi-asserted-by":"publisher","first-page":"8271","DOI":"10.1038\/s41598-020-65207-6","volume":"10","author":"Sun L.H.","year":"2020","unstructured":"Sun L.H.; Tian D.; Yang Z.C.; Li J.L.; Exosomal miR-21 promotes proliferation, invasion and therapy resistance of colon adenocarcinoma cells through its target PDCD4. Sci Rep  2020,10(1),8271","journal-title":"Sci Rep"},{"key":"ref=37","doi-asserted-by":"publisher","first-page":"2040","DOI":"10.1016\/j.cmet.2021.09.002","volume":"33","author":"Morrissey S.M.","year":"2021","unstructured":"Morrissey S.M.; Zhang F.; Ding C.; Montoya-Durango D.E.; Hu X.; Yang C.; Wang Z.; Yuan F.; Fox M.; Zhang H.; Guo H.; Tieri D.; Kong M.; Watson C.T.; Mitchell R.A.; Zhang X.; McMasters K.M.; Huang J.; Yan J.; Tumor-derived exosomes drive immunosuppressive macrophages in a pre-metastatic niche through glycolytic do,minant metabolic reprogramming. Cell Metab  2021,33(10),2040-2058.e10","journal-title":"Cell Metab"},{"key":"ref=38","doi-asserted-by":"publisher","first-page":"176831","DOI":"10.1016\/j.ejphar.2024.176831","volume":"979","author":"Liu J.","year":"2024","unstructured":"Liu J.; Qin J.; Liang L.; Zhang X.; Gao J.; Hao Y.; Zhao P.; Novel insights into the regulation of exosomal PD-L1 in cancer: From generation to clinical application. Eur J Pharmacol  2024,979,176831","journal-title":"Eur J Pharmacol"},{"key":"ref=39","doi-asserted-by":"publisher","first-page":"1401","DOI":"10.2147\/DDDT.S221518","volume":"14","author":"Muhamad N.","year":"2020","unstructured":"Muhamad N.; Na-Bangchang K.; Metabolite profiling in anticancer drug development: A systematic review. Drug Des Devel Ther  2020,14,1401-1444","journal-title":"Drug Des Devel Ther"},{"key":"ref=40","doi-asserted-by":"publisher","first-page":"1326776","DOI":"10.3389\/fphar.2024.1326776","volume":"15","author":"Shubbar Q.","year":"2024","unstructured":"Shubbar Q.; Alchakee A.; Issa K.W.; Adi A.J.; Shorbagi A.I.; Saber-Ayad M.; From genes to drugs: CYP2C19 and pharmacogenetics in clinical practice. Front Pharmacol  2024,15,1326776","journal-title":"Front Pharmacol"},{"key":"ref=41","doi-asserted-by":"publisher","first-page":"1958","DOI":"10.3390\/cells13231958","volume":"13","author":"Mokhosoev I.M.","year":"2024","unstructured":"Mokhosoev I.M.; Astakhov D.V.; Terentiev A.A.; Moldogazieva N.T.; Human cytochrome P450 cancer-related metabolic activities and gene polymorphisms: A review. Cells  2024,13(23),1958","journal-title":"Cells"},{"key":"ref=42","doi-asserted-by":"publisher","first-page":"1367","DOI":"10.1016\/j.gendis.2022.02.007","volume":"10","author":"Anand U.","year":"2023","unstructured":"Anand U.; Dey A.; Chandel A.K.S.; Dewanjee S.; Vallamkondu J.; P\u00e9rez de la Lastra J.M.; Cancer chemotherapy and beyond: Current status, drug candidates, associated risks and progress in targeted therapeutics. Genes Dis  2023,10(4),1367-1401","journal-title":"Genes Dis"},{"key":"ref=43","doi-asserted-by":"publisher","first-page":"315","DOI":"10.1007\/s00280-019-03867-6","volume":"84","author":"Jin G.","year":"2019","unstructured":"Jin G.; Liu Y.; Zhang J.; Bian Z.; Yao S.; Fei B.; Zhou L.; Yin Y.; Huang Z.; A panel of serum exosomal microRNAs as predictive markers for chemoresistance in advanced colorectal cancer. Cancer Chemother Pharmacol  2019,84(2),315-325","journal-title":"Cancer Chemother Pharmacol"},{"key":"ref=44","doi-asserted-by":"publisher","first-page":"452","DOI":"10.1016\/j.omtn.2020.06.016","volume":"21","author":"Feng Y.","year":"2020","unstructured":"Feng Y.; Zhong M.; Tang Y.; Liu X.; Liu Y.; Wang L.; Zhou H.; The role and underlying mechanism of exosomal CA1 in chemotherapy resistance in diffuse large B cell lymphoma. Mol Ther Nucleic Acids  2020,21,452-463","journal-title":"Mol Ther Nucleic Acids"},{"key":"ref=45","doi-asserted-by":"publisher","first-page":"1290","DOI":"10.1186\/s12885-021-09020-y","volume":"21","author":"Jiang L.","year":"2021","unstructured":"Jiang L.; Zhang Y.; Guo L.; Liu C.; Wang P.; Ren W.; Exosomal microRNA-107 reverses chemotherapeutic drug resistance of gastric cancer cells through HMGA2\/mTOR\/P-gp pathway. BMC Cancer  2021,21(1),1290","journal-title":"BMC Cancer"},{"key":"ref=46","doi-asserted-by":"publisher","first-page":"104592","DOI":"10.1016\/j.yexmp.2020.104592","volume":"118","author":"Mowla M.","year":"2021","unstructured":"Mowla M.; Hashemi A.; Functional roles of exosomal miRNAs in multi-drug resistance in cancer chemotherapeutics. Exp Mol Pathol  2021,118,104592","journal-title":"Exp Mol Pathol"},{"key":"ref=47","doi-asserted-by":"publisher","first-page":"120","DOI":"10.1186\/s13046-021-01901-1","volume":"40","author":"Yang Q.","year":"2021","unstructured":"Yang Q.; Zhao S.; Shi Z.; Zhou D.; Zhang J.; Chemotherapy-elicited exosomal miR-378a-3p and miR-378d promote breast cancer stemness and chemoresistance via the activation of EZH2\/STAT3 signaling. J Exp Clin Cancer Res  2021,40(1),120","journal-title":"J Exp Clin Cancer Res"},{"key":"ref=48","doi-asserted-by":"publisher","first-page":"220","DOI":"10.1002\/ijc.30669","volume":"141","author":"Bach D.H.","year":"2017","unstructured":"Bach D.H.; Hong J.Y.; Park H.J.; Lee S.K.; The role of exosomes and miRNAs in drug\u2010resistance of cancer cells. Int J Cancer  2017,141(2),220-230","journal-title":"Int J Cancer"},{"key":"ref=49","doi-asserted-by":"publisher","first-page":"2095","DOI":"10.1002\/jcp.30697","volume":"237","author":"Taghvimi S.","year":"2022","unstructured":"Taghvimi S.; Vakili O.; Soltani Fard E.; Khatami S.H.; Karami N.; Taheri-Anganeh M.; Salehi M.; Negahdari B.; Ghasemi H.; Movahedpour A.; Exosomal microRNAs and long noncoding RNAs: Novel mediators of drug resistance in lung cancer. J Cell Physiol  2022,237(4),2095-2106","journal-title":"J Cell Physiol"},{"key":"ref=50","doi-asserted-by":"publisher","first-page":"1152672","DOI":"10.3389\/fphar.2023.1152672","volume":"14","author":"Rezaee M.","year":"2023","unstructured":"Rezaee M.; Mohammadi F.; Keshavarzmotamed A.; Alimohammadi M.; Azadi A.; Moussavi N.; Asemi Z.; Aminianfar A.; Mirzaei H.; Mafi A.; The landscape of exosomal non-coding RNAs in breast cancer drug resistance, focusing on underlying molecular mechanisms. Front Pharmacol  2023,14,1152672","journal-title":"Front Pharmacol"},{"key":"ref=51","doi-asserted-by":"publisher","first-page":"987","DOI":"10.1038\/s41419-020-03189-z","volume":"11","author":"Dong X.","year":"2020","unstructured":"Dong X.; Bai X.; Ni J.; Graham P.; Li Y.; Exosomes and breast cancer drug resistance. Cell Death Dis  2020,11(11),987","journal-title":"Cell Death Dis"},{"key":"ref=52","doi-asserted-by":"publisher","first-page":"1473","DOI":"10.3390\/ijms23031473","volume":"23","author":"Lampropoulou D.I.","year":"2022","unstructured":"Lampropoulou D.I.; Pliakou E.; Aravantinos G.; Filippou D.; Gazouli M.; The role of exosomal non-coding RNAs in colorectal cancer drug resistance. Int J Mol Sci  2022,23(3),1473","journal-title":"Int J Mol Sci"},{"key":"ref=53","doi-asserted-by":"publisher","first-page":"e12500","DOI":"10.1200\/JCO.2024.42.16_suppl.e12500","volume":"42","author":"Yang S.","year":"2024","unstructured":"Yang S.; Zhu B.; Wu J.; Cheng T.; Zheng L.; Chen W.; Exosome-delivered microRNAs confer adriamycin-resistance through modulating the immune and metabolism-related gene PTEN in HER2-negative breast cancer. J Clin Oncol  2024,42(16_suppl),e12500-e12500","journal-title":"J Clin Oncol"},{"key":"ref=54","doi-asserted-by":"publisher","first-page":"167","DOI":"10.7150\/ijbs.78321","volume":"19","author":"Lu Z.","year":"2023","unstructured":"Lu Z.; Chen Y.; Luo W.; Xia L.; Li G.; Exosomes in genitourinary cancers: Emerging mediators of drug resistance and promising biomarkers. Int J Biol Sci  2023,19(1),167-182","journal-title":"Int J Biol Sci"},{"key":"ref=55","doi-asserted-by":"publisher","first-page":"1092705","DOI":"10.3389\/fonc.2022.1092705","volume":"12","author":"Luo J.","year":"2023","unstructured":"Luo J.; Li Y.; Zhang T.; Qiu Q.; Song Y.; Wan S.; Extrachromosomal circular DNA in cancer drug resistance and its potential clinical implications. Front Oncol  2023,12,1092705","journal-title":"Front Oncol"},{"key":"ref=56","doi-asserted-by":"publisher","first-page":"628","DOI":"10.1016\/j.sjbs.2020.10.052","volume":"28","author":"Aboul-Soud M.A.M.","year":"2021","unstructured":"Aboul-Soud M.A.M.; Alzahrani A.J.; Mahmoud A.; Decoding variants in drug-metabolizing enzymes and transporters in solid tumor patients by whole-exome sequencing. Saudi J Biol Sci  2021,28(1),628-634","journal-title":"Saudi J Biol Sci"},{"key":"ref=57","doi-asserted-by":"publisher","first-page":"472","DOI":"10.3389\/fonc.2020.00472","volume":"10","author":"Guo Q.","year":"2020","unstructured":"Guo Q.; Wang H.; Yan Y.; Liu Y.; Su C.; Chen H.; Yan Y.; Adhikari R.; Wu Q.; Zhang J.; The role of exosomal microRNA in cancer drug resistance. Front Oncol  2020,10,472","journal-title":"Front Oncol"},{"key":"ref=58","doi-asserted-by":"publisher","first-page":"211","DOI":"10.1055\/s-0028-1103272","volume":"39","author":"Daood M.","year":"2008","unstructured":"Daood M.; Tsai C.; Ahdab-Barmada M.; Watchko J.; ABC transporter (P-gp\/ABCB1, MRP1\/ABCC1, BCRP\/ABCG2) expression in the developing human CNS. Neuropediatrics  2008,39(4),211-218","journal-title":"Neuropediatrics"},{"key":"ref=59","doi-asserted-by":"publisher","first-page":"58","DOI":"10.5732\/cjc.011.10329","volume":"31","author":"Sodani K.","year":"2012","unstructured":"Sodani K.; Patel A.; Kathawala R.J.; Chen Z.S.; Multidrug resistance associated proteins in multidrug resistance. Chin J Cancer  2012,31(2),58-72","journal-title":"Chin J Cancer"},{"key":"ref=60","doi-asserted-by":"publisher","first-page":"216","DOI":"10.1016\/j.taap.2004.10.012","volume":"204","author":"Leslie E.M.","year":"2005","unstructured":"Leslie E.M.; Deeley R.G.; Cole S.P.C.; Multidrug resistance proteins: Role of P-glycoprotein, MRP1, MRP2, and BCRP (ABCG2) in tissue defense. Toxicol Appl Pharmacol  2005,204(3),216-237","journal-title":"Toxicol Appl Pharmacol"},{"key":"ref=61","doi-asserted-by":"publisher","first-page":"1069","DOI":"10.1016\/j.ncrna.2024.06.010","volume":"9","author":"Li X.","year":"2024","unstructured":"Li X.; Wu Y.; Jin Y.; Exosomal LncRNAs and CircRNAs in lung cancer: Emerging regulators and potential therapeutic targets. Noncoding RNA Res  2024,9(4),1069-1079","journal-title":"Noncoding RNA Res"},{"key":"ref=62","doi-asserted-by":"publisher","first-page":"e16841","DOI":"10.1371\/journal.pone.0016841","volume":"6","author":"Yamamoto M.","year":"2011","unstructured":"Yamamoto M.; Kondo E.; Takeuchi M.; Kibata M.; Nakamura S.; miR-155, a modulator of FOXO3a protein expression, is underexpressed and cannot be upregulated by stimulation of HOZOT, a line of multifunctional Treg. PLoS One  2011,6(2),e16841","journal-title":"PLoS One"},{"key":"ref=63","doi-asserted-by":"publisher","first-page":"851","DOI":"10.3892\/mmr.2019.10340","volume":"20","author":"Ko\u0142at D.","year":"2019","unstructured":"Ko\u0142at D.; Hammouz R.; Bednarek A.; P\u0142uciennik E.; Exosomes as carriers transporting long non-coding RNAs: Molecular characteristics and their function in cancer (Review). Mol Med Rep  2019,20(2),851-862","journal-title":"Mol Med Rep"},{"key":"ref=64","doi-asserted-by":"publisher","first-page":"151","DOI":"10.1016\/j.bbcan.2015.07.001","volume":"1856","author":"Bhan A.","year":"2015","unstructured":"Bhan A.; Mandal S.S.; LncRNA HOTAIR: A master regulator of chromatin dynamics and cancer. Biochim Biophys Acta Rev Cancer  2015,1856(1),151-164","journal-title":"Biochim Biophys Acta Rev Cancer"},{"key":"ref=65","doi-asserted-by":"publisher","first-page":"1390","DOI":"10.1038\/s12276-022-00855-4","volume":"54","author":"Wang X.","year":"2022","unstructured":"Wang X.; Huang J.; Chen W.; Li G.; Li Z.; Lei J.; The updated role of exosomal proteins in the diagnosis, prognosis, and treatment of cancer. Exp Mol Med  2022,54(9),1390-1400","journal-title":"Exp Mol Med"},{"key":"ref=66","doi-asserted-by":"publisher","first-page":"166484","DOI":"10.1016\/j.bbadis.2022.166484","volume":"1868","author":"Jahangiri B.","year":"2022","unstructured":"Jahangiri B.; Saei A.K.; Obi P.O.; Asghari N.; Lorzadeh S.; Hekmatirad S.; Rahmati M.; Velayatipour F.; Asghari M.H.; Saleem A.; Moosavi M.A.; Exosomes, autophagy and ER stress pathways in human diseases: Cross-regulation and therapeutic approaches. Biochim Biophys Acta Mol Basis Dis  2022,1868(10),166484","journal-title":"Biochim Biophys Acta Mol Basis Dis"},{"key":"ref=67","doi-asserted-by":"publisher","first-page":"022005","DOI":"10.1088\/1748-605X\/abde70","volume":"16","author":"Le M.C.N.","year":"2021","unstructured":"Le M.C.N.; Fan H.Z.; Exosome isolation using nanostructures and microfluidic devices. Biomed Mater  2021,16(2),022005","journal-title":"Biomed Mater"},{"key":"ref=68","doi-asserted-by":"publisher","first-page":"4997","DOI":"10.1002\/pmic.200900351","volume":"9","author":"Mathivanan S.","year":"2009","unstructured":"Mathivanan S.; Simpson R.J.; ExoCarta: A compendium of exosomal proteins and RNA. Proteomics  2009,9(21),4997-5000","journal-title":"Proteomics"},{"key":"ref=69","doi-asserted-by":"publisher","first-page":"1030","DOI":"10.3389\/fonc.2020.01030","volume":"10","author":"Nicora G.","year":"2020","unstructured":"Nicora G.; Vitali F.; Dagliati A.; Geifman N.; Bellazzi R.; Integrated multi-omics analyses in oncology: A review of machine learning methods and tools. Front Oncol  2020,10,1030","journal-title":"Front Oncol"},{"key":"ref=70","doi-asserted-by":"publisher","first-page":"e12404","DOI":"10.1002\/jev2.12404","volume":"13","author":"Welsh J.A.","year":"2024","unstructured":"Welsh J.A.; Goberdhan D.C.I.; O\u2019Driscoll L.; Buzas E.I.; Blenkiron C.; Bussolati B.; Cai H.; Di Vizio D.; Driedonks T.A.P.; Erdbr\u00fcgger U.; Falcon-Perez J.M.; Fu Q.L.; Hill A.F.; Lenassi M.; Lim S.K.; Mahoney M.G.; Mohanty S.; M\u00f6ller A.; Nieuwland R.; Ochiya T.; Sahoo S.; Torrecilhas A.C.; Zheng L.; Zijlstra A.; Abuelreich S.; Bagabas R.; Bergese P.; Bridges E.M.; Brucale M.; Burger D.; Carney R.P.; Cocucci E.; Crescitelli R.; Hanser E.; Harris A.L.; Haughey N.J.; Hendrix A.; Ivanov A.R.; Jovanovic-Talisman T.; Kruh-Garcia N.A.; Ku\u2019ulei-Lyn Faustino V.; Kyburz D.; L\u00e4sser C.; Lennon K.M.; L\u00f6tvall J.; Maddox A.L.; Martens-Uzunova E.S.; Mizenko R.R.; Newman L.A.; Ridolfi A.; Rohde E.; Rojalin T.; Rowland A.; Saftics A.; Sandau U.S.; Saugstad J.A.; Shekari F.; Swift S.; Ter-Ovanesyan D.; Tosar J.P.; Useckaite Z.; Valle F.; Varga Z.; van der Pol E.; van Herwijnen M.J.C.; Wauben M.H.M.; Wehman A.M.; Williams S.; Zendrini A.; Zimmerman A.J.; Th\u00e9ry C.; Witwer K.W.; Minimal information for studies of extracellular vesicles (MISEV2023): From basic to advanced approaches. J Extracell Vesicles  2024,13(2),e12404","journal-title":"J Extracell Vesicles"},{"key":"ref=71","doi-asserted-by":"publisher","first-page":"18374","DOI":"10.3402\/jev.v1i0.18374","volume":"1","author":"Simpson R.J.","year":"2012","unstructured":"Simpson R.J.; Kalra H.; Mathivanan S.; ExoCarta as a resource for exosomal research. J Extracell Vesicles  2012,1(1),18374","journal-title":"J Extracell Vesicles"},{"key":"ref=72","doi-asserted-by":"publisher","first-page":"D118","DOI":"10.1093\/nar\/gkab1085","volume":"50","author":"Lai H.","year":"2022","unstructured":"Lai H.; Li Y.; Zhang H.; Hu J.; Liao J.; Su Y.; Li Q.; Chen B.; Li C.; Wang Z.; Li Y.; Wang J.; Meng Z.; Huang Z.; Huang S.; exoRBase 2.0: An atlas of mRNA, lncRNA and circRNA in extracellular vesicles from human biofluids. Nucleic Acids Res  2022,50(D1),D118-D128","journal-title":"Nucleic Acids Res"},{"key":"ref=73","doi-asserted-by":"publisher","first-page":"D543","DOI":"10.1093\/nar\/gkae1011","volume":"53","author":"Perez-Riverol Y.","year":"2025","unstructured":"Perez-Riverol Y.; Bandla C.; Kundu D.J.; Kamatchinathan S.; Bai J.; Hewapathirana S.; John N.S.; Prakash A.; Walzer M.; Wang S.; Vizca\u00edno J.A.; The PRIDE database at 20 years: 2025 update. Nucleic Acids Res  2025,53(D1),D543-D553","journal-title":"Nucleic Acids Res"},{"key":"ref=74","doi-asserted-by":"publisher","first-page":"216","DOI":"10.1186\/s12943-022-01684-9","volume":"21","author":"Guo T.","year":"2022","unstructured":"Guo T.; Tang X.H.; Gao X.Y.; Xing X.F.; Li Z.Y.; Ji J.F.; A liquid biopsy signature of circulating exosome-derived mRNAs, miRNAs and lncRNAs predict therapeutic efficacy to neoadjuvant chemotherapy in patients with advanced gastric cancer. Mol Cancer  2022,21(1),216","journal-title":"Mol Cancer"},{"key":"ref=75","doi-asserted-by":"publisher","first-page":"216","DOI":"10.1111\/bcp.13793","volume":"85","author":"Rowland A.","year":"2019","unstructured":"Rowland A.; Ruanglertboon W.; van Dyk M.; Wijayakumara D.; Wood L.S.; Meech R.; Mackenzie P.I.; Rodrigues A.D.; Marshall J.C.; Sorich M.J.; Plasma extracellular nanovesicle (exosome)\u2010derived biomarkers for drug metabolism pathways: A novel approach to characterize variability in drug exposure. Br J Clin Pharmacol  2019,85(1),216-226","journal-title":"Br J Clin Pharmacol"},{"key":"ref=76","doi-asserted-by":"publisher","first-page":"222","DOI":"10.1002\/cpt.2102","volume":"109","author":"Achour B.","year":"2021","unstructured":"Achour B.; Al-Majdoub Z.M.; Grybos-Gajniak A.; Lea K.; Kilford P.; Zhang M.; Knight D.; Barber J.; Schageman J.; Rostami-Hodjegan A.; Liquid biopsy enables quantification of the abundance and interindividual variability of hepatic enzymes and transporters. Clin Pharmacol Ther  2021,109(1),222-232","journal-title":"Clin Pharmacol Ther"},{"key":"ref=77","doi-asserted-by":"publisher","first-page":"1710899","DOI":"10.1080\/20013078.2019.1710899","volume":"9","author":"Cordonnier M.","year":"2020","unstructured":"Cordonnier M.; Nardin C.; Chanteloup G.; Derangere V.; Algros M.P.; Arnould L.; Garrido C.; Aubin F.; Gobbo J.; Tracking the evolution of circulating exosomal-PD-L1 to monitor melanoma patients. J Extracell Vesicles  2020,9(1),1710899","journal-title":"J Extracell Vesicles"},{"key":"ref=78","doi-asserted-by":"publisher","first-page":"186","DOI":"10.1186\/s13046-022-02379-1","volume":"41","author":"de Miguel-Perez D.","year":"2022","unstructured":"de Miguel-Perez D.; Russo A.; Arrieta O.; Hirsch F.R.; Mack P.C.; Serrano M.J.; Adamo V.; Colen R.R.; Rolfo C.; Extracellular vesicle PD-L1 dynamics predict durable response to immune-checkpoint inhibitors and survival in patients with non-small cell lung cancer. J Exp Clin Cancer Res  2022,41(1),186","journal-title":"J Exp Clin Cancer Res"},{"key":"ref=79","doi-asserted-by":"publisher","first-page":"1495","DOI":"10.3389\/fonc.2020.01495","volume":"10","author":"Han J.","year":"2020","unstructured":"Han J.; Sun W.; Liu R.; Zhou Z.; Zhang H.; Chen X.; Ba Y.; Plasma exosomal miRNA expression profile as oxaliplatin-based chemoresistant biomarkers in colorectal adenocarcinoma. Front Oncol  2020,10,1495","journal-title":"Front Oncol"},{"key":"ref=80","doi-asserted-by":"publisher","first-page":"e95240","DOI":"10.1371\/journal.pone.0095240","volume":"9","author":"Chen W.","year":"2014","unstructured":"Chen W.; Liu X.; Lv M.; Luo Z.; Wu J.Z.; Tang J.H.; Exosomes from drug-resistant breast cancer cells transmit chemoresistance by a horizontal transfer of microRNAs. PLoS One  2014,9(4),e95240","journal-title":"PLoS One"}],"container-title":["Current Drug Metabolism"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.eurekaselect.com\/article\/download?doi=10.2174\/0113892002399475260223055432","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.eurekaselect.com\/251568\/article","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.eurekaselect.com\/article\/download?doi=10.2174\/0113892002399475260223055432","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,10,2]],"date-time":"2026-10-02T04:20:53Z","timestamp":1790914853000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.eurekaselect.com\/251568\/article"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,5]]},"references-count":80,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2026,5]]}},"alternative-id":["LiveAll1"],"URL":"https:\/\/doi.org\/10.2174\/0113892002399475260223055432","relation":{},"ISSN":["1389-2002"],"issn-type":[{"value":"1389-2002","type":"print"}],"subject":[],"published":{"date-parts":[[2026,5]]},"assertion":[{"value":"Peer Reviewed","order":0,"name":"review_status","label":"Review Status","group":{"name":"peer_review_details","label":"Peer Review Details"}},{"value":"Double blind","order":1,"name":"review_process","label":"Review Process","group":{"name":"peer_review_details","label":"Peer Review Details"}},{"value":"Checked with iThenticate","order":0,"name":"screening_status","label":"Screening Status","group":{"name":"plagiarism_screening","label":"Plagiarism Screening"}},{"value":"2025-06-13","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2025-09-16","order":1,"name":"revised","label":"Revised","group":{"name":"publication_history","label":"Publication History"}},{"value":"2025-09-26","order":2,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2026-09-02","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}